SALIM VIRANI to Apolipoprotein C-III
This is a "connection" page, showing publications SALIM VIRANI has written about Apolipoprotein C-III.
Connection Strength
0.299
-
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Curr Atheroscler Rep. 2020 06 03; 22(7):25.
Score: 0.174
-
LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J Lipid Res. 2012 Mar; 53(3):556-560.
Score: 0.097
-
Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis. 2014 Jun; 234(2):249-53.
Score: 0.028